Shares of Moderna and Merck climbed by up to 177% on Wednesday following positive results from a late-stage clinical trial for their experimental custom cancer vaccine. This significant market jump caused short sellers, who had wagered against the company, to lose approximately $5.5 billion, or nearly ₹52,564 crore. The surge is particularly notable as Moderna's stock had been struggling for some time due to falling demand for its COVID-19 shots.

by shortkt.com✓

3 घंटे पहले